earnings
confidence high
sentiment positive
materiality 0.65
BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M
BIOLIFE SOLUTIONS INC
2024-Q2 EPS reported
-$0.68
revenue$55,107,000
- Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
- GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.
- GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.
- Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.
- Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M.